본문 바로가기
KERD
논문KCI 등재

마우스 동종 줄기세포 유래 수지상 세포를 이용한 백신의 흑색종 폐암 전이 모델에서의 항암 효과 및 기전 연구

Anti-cancer Effect of Hematopoietic Stem Cell-derived Allogeneic-DC Vaccine in Melanoma Metastasis Model

이영준|이현아|손혜진|백소영|이강은|김명주
대한면역학회 (The Korean Association of Immunologists)|2006.06|Immune Network|제6권 제3호|pp. 154-162

2

조회

0

다운로드

0

인용

0

참고문헌

초록

Abstract

Background: Dendritic cell (DC)-based cancer immunotherapy is studied for several years. However, it is mainly derived from autologous PBMC or leukapheresis from patient, which has limitations about yield and ability of DC production according to individual status. In order to solve these problems, inquiries about allogeneic DCs are performed but there are no preclinical trial answers for effect or toxicity of allogeneic DC to use for clinical trial. In this study, we compared the anti-tumor effect of allogeneic and autologous DCs from mouse bone marrow stem cells in mouse metastatic melanoma model. Methods: B16F10 melanoma cells (5 104/mouse) were injected intravenously into the C57BL/6 mouse. Therapeutic DCs were differentiated from autologous (C57BL/6: CDC) or allogeneic (B6C3F1: BDC) bone marrow stem cells with GM-CSF, SCF and IL-4 for 13days and pulsed with B16F10 tumor cell lysate (Blys) for 18hrs. DC intra-peritoneal injections began on the 8th day after the tumor cell injection by twice with one week interval. Results: Anti-tumor response was observed by DC treatment without any toxicity especially in allogeneic DC treated mice (tumor burden score: 2.667 0.184, 2.500 0.463, 2.000 0.286, 1.500 0.286, 1.667 0.297 for saline, CDC/unpulsed-DC: U-DC, CDC/Blys-DC, BDC/U-DC and BDC/Blys-DC, respectively). IFN-γ secretion was significantly increased in allogeneic DC group stimulated with B16F10 cell lysate (2,643.3 5,89.7, 8,561.5 2,204.9. 6,901.2 141.1 pg/1 106 cells for saline, BDC/U-DC and BDC/Blys-DC, respectively) with increased NK cell activity. Conclusion: Conclusively, promising data was obtained that allogeneic DC can be used for DC-based cancer immunotherapy. (Immune Network 2006;6(3):154-162)

참고문헌 (34)

  1. "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", 2, pp.52~58 (1996)
  2. "Effect of dendritic cell based cancer vaccine using allogeneic tumor cell lysate in melanoma pulmonary metastasis model", 5, pp.163~171 (2005)
  3. "Cellular immunotherapy with dendritic cells in cancer", 22, pp.501~513 (2004)
  4. "Generation of dendritic cells from positively selected CD14 monocytes for anti- tumor immunotherapy", 45, pp.1419~1428 (2004)
  5. "Dendritic cell immunotherapy", 10, pp.475~480 (2004)
  6. "Dendritic cell based cancer immunotherapy", 4, pp.44~52 (2004)
  7. "Clinical-grade manufacturing of DC from CD14 precursors", 6, pp.563~570 (2004)
  8. "Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells", 195, pp.1279~1288 (2002)
  9. "Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells", 8, pp.3369~3376 (2002)
  10. "Durable complete clinical responses in a phase I", II trial using an autologous melanoma cell, pp.2003, 52[DOI]
  11. "A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer", 52, pp.155~161 (2003)
  12. "CD34 -derived CD11c BDCA-1 CD123 DC", 8, pp.130~140 (2006)
  13. "Implication of delayed TNF-α exposure on dendritic cell maturation and expansion from cryopreserved cord blood CD34 hematopoietic progenitors", 293, pp.169~182 (2004)
  14. "Selective generation of different dendritic cell precursors from CD34 cells by interleukin-6 and interleukin-3", 22, pp.725~740 (2004)
  15. "Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells", 75, pp.217~227 (2003)
  16. "Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood", 23, pp.5225~5230 (2005)
  17. "Production of myeloid dendritic cells (DC) pulsed with tumor- specific idiotype protein for vaccination of patients with multiple myeloma", 8, pp.277~289 (2006)
  18. "Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia", 19, pp.1621~1627 (2005)
  19. "Allogeneic dendritic cells fused with tumor cells", 14, pp.483~494 (2003)
  20. "Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases", 100, pp.1611~1618 (2002)
  21. "Phorbol ester effects on splenic lymphocyte composition and cytotoxic T cell activities of SSIN mice", 17, pp.2617~2624 (1996)
  22. "Modulating the immune response with dendritic cells and their growth factors", 22, pp.41~47 (2001)
  23. "Immnotherapy of melanoma", 13, pp.391~400 (2003)
  24. "Immunocell therapy for lung cancer", 5, pp.36~44 (2005)
  25. "Dendritic cell regulation of TH1-TH2 development", 1, pp.199~204 (2000)
  26. "Concept of lymphoid versus myeloid dendritic cell lineages revisited", 96, pp.2511~2519 (2000)
  27. "Leukemic dendritic cells", 16, pp.2197~2204 (2002)
  28. "Mature human langerhans cells derived from CD34 hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte- derived dendritic cells", 173, pp.2780~2791 (2004)
  29. "Regulatory T cells and mechanisms of immune system control", 10, pp.801~805 (2004)
  30. "Dendritic cell-induced activation of adaptive and innate antitumor immunity", 171, pp.5842~5852 (2003)
  31. "NK cell activation by dendritic cell vaccine", 55, pp.1122~1131 (2006)
  32. "Dendritic cells mediate NK cell help for Th1 and CTL responses", 171, pp.2366~2373 (2003)
  33. "Helper role of NK cells during the induction of anticancer responses by dendritic cells", 42, pp.535~539 (2005)
  34. "The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions", 174, pp.727~734 (2005)

관련 논문AI추천

동종 종양 세포 용해액을 이용한 수지상 세포 항암 백신의 흑색종 폐암 전이 모델에서의 효과 연구권영도, 김명주, 백소영, 이영준, 이현아, 인소희, 최옥미대한면역학회 · Immune Network2005 · 제5권 제3호폐암의 면역세포 치료: 동물 모델에서 수지상 세포를 이용한 Adjuvant Therapy 가능성 연구김명주, 백소영, 이석재, 이현아, 인소희대한면역학회 · Immune Network2005 · 제5권 제1호수지상세포를 이용한 항암 면역 치료: 생쥐 신장암 모델을 이용한 연구백소영, 이현아, 이홍기, 정철원, 최광민대한면역학회 · Immune Network2004 · 제4권 제1호수지상세포를 이용한 편평세포암종 예방백신고예정, 손영익, 이치규, 정승원대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2004 · 제47권 제12호Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model; Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC김명주, 백소영, 이석재, 이현아대한면역학회 · Immune Network2012 · 제12권 제6호IL12 p40 형광 리포터 생쥐 시스템을 이용한 B16 F/T 항암 백신의 면역활성 연구윤대선, 윤지희, 홍석만대한체질인류학회 · 해부·생물인류학2007 · 제20권 제2호

이 간행물의 다른 논문 (11건)

p38 Kinase Regulates Nitric Oxide-induced Dedifferentiation and Cyclooxygenase-2 Expression of Articular Chondrocytes김송자, 정선우, 조삼래, 유선미pp. 117-122Ectopic Expression of Caveolin-1 Induces COX-2 Expression in Rabbit Articular Chondrocytes via MAP Kinase PathwaySong-Ja Kimpp. 123-127Apoptosis-Induced Gene Profiles of a Myeloma Cell P3-X63-Ag8.653Hye-Seungn Bahng, Yong-Hoon Chungpp. 128-137덱사메타손이 생쥐 B세포의 세포 표면 인식자와 분화에 미치는 영향차창일, 여승근, 박동춘pp. 138-144종양 세포 용해액에 따른 수지상세포 유도 항원 특이 면역반응 차이의 기전 연구이현아, 손혜진, 김명주, 백소영, 이강은pp. 145-153
원문 보기